PLUS THERAPEUTICS Inc.
PSTV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PSTV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PSTV
Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, with a lead product candidate and a diagnostic test.
Key risk: Capital raising uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 6 clinical trials for PLUS THERAPEUTICS Inc..
Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, with a lead product candidate and a diagnostic test.
- Plus Therapeutics develops targeted radiotherapeutics and advanced platform technologies for CNS cancers [sec_mda · as of 2025-03-31].
- As of 2026-06-30, the company reported cash & equivalents of $2.4M, total revenue of $0.4M, and a net loss of -$9.0M [sec].
- The company's liquidity depends on raising additional capital through equity offerings, debt financings, or collaborations, with no assurance of future funding [sec_mda · as of 2026-08-14].
- The company's CNSide Test is a key asset under development, with its utility affecting funding requirements [sec_mda · as of 2026-08-14].
What works
- The company has a focused pipeline targeting CNS cancers with novel radioactive drug formulations and medical devices [sec_mda · as of 2025-03-31].
- The CNSide Test represents a potential diagnostic platform that could complement its therapeutic candidates [sec_mda · as of 2026-08-14].
What to weigh
- The company has a history of net losses and negative working capital, with a net loss of -$9.0M for the six months ended 2026-06-30 [sec].
- The company faces significant uncertainty in raising additional capital, which is critical for operations and Nasdaq compliance [sec_mda · as of 2026-08-14].
- Cash and equivalents were only $2.4M as of 2026-06-30, indicating limited near-term liquidity [sec].
From the filings
Quoted directly from source documents.
The company develops targeted radiotherapeutics for CNS cancers.
“Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ("CNS") cancers.”
SEC MD&A · March 31, 2025
The company's inability to raise capital would materially impact operations.
“Our inability to raise additional cash would have a material adverse impact on our operations, implementation of our strategy and ability to maintain compliance with applicable requirements, including Nasdaq listing rules.”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Capital raising uncertainty — No assurance of raising additional capital; failure would materially harm operations and Nasdaq listing [sec_mda · as of 2026-08-14].
- Limited cash runway — Cash of $2.4M as of 2026-06-30 may be insufficient to fund operations without new financing [sec].
- Dependence on clinical progress — Funding needs depend on progress and timing of clinical trials and regulatory approvals [sec_mda · as of 2026-08-14].
What to watch
- Ability to raise additional capital through equity, debt, or collaborations [sec_mda · as of 2026-08-14].
- Progress and results of ongoing clinical trials for CNS cancer radiotherapeutics [sec_mda · as of 2026-08-14].
- Development and commercialization milestones for the CNSide Test [sec_mda · as of 2026-08-14].
- Regulatory interactions with the FDA and EMA for product candidates [sec · filed 2026-01-09].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run PLUS THERAPEUTICS Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PLUS THERAPEUTICS Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
3.9 months
D/E 1.57 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$430
| Holder | Shares | Value |
|---|---|---|
| sbi securities co., ltd. | 2,644 | $430 |
Short Interest
as of May 12, 2026- % of float
- 18.0%
- Days to cover
- 2.1
- Shares short
- 1,232,913
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PSTV short interestGovernance
Frequently asked questions
What is the AI investment thesis for PLUS THERAPEUTICS Inc.?
Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, with a lead product candidate and a diagnostic test.
What is PLUS THERAPEUTICS Inc.'s lead drug candidate?
PLUS THERAPEUTICS Inc.'s most advanced tracked candidate is 188rnl-bam (Preclinical) for Solid organ cancers including primary and secondary liver cancers.
Who is the CEO of PLUS THERAPEUTICS Inc.?
Dr. Marc H. Hedrick M.B.A., M.D. is the chief executive officer of PLUS THERAPEUTICS Inc. (PSTV).
Where is PLUS THERAPEUTICS Inc. headquartered?
PLUS THERAPEUTICS Inc. (PSTV) is headquartered in Houston, TX, United States.
What therapeutic areas does PLUS THERAPEUTICS Inc. focus on?
PLUS THERAPEUTICS Inc. develops therapies across Oncology, Neurology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.